To investigate the predictive capacity of the apparent diffusion coefficient (ADC) as a biomarker of radiation response in brain metastases. Seventy brain metastases from 42 patients treated with either stereotactic radiosurgery or whole brain radiotherapy were imaged at baseline, 1 week, and 1 month post-treatment using diffusion-weighted MRI. Mean and median relative ADC for metastases was calculated by normalizing ADC measurements to baseline ADC. At 1 year post-treatment, or last available follow-up MRI, volume criteria determined final tumour response status. Uni- and multivariate analysis was used to account for factors associated with tumour response at 1 week and 1 month. A generalized estimating equations model took into consideration multiple tumours per subject. Optimal thresholds that distinguished responders from non-responders, as well as sensitivity and specificity were determined by receiver operator characteristic analysis and Youden's index. Lower relative ADC values distinguished responders from non-responders at 1 week and 1 month (P < 0.05). Optimal cut-off values for response were 1.060 at 1 week with a sensitivity and specificity of 75.0 and 56.3 %, respectively. At 1 month, the cut-off was 0.971 with a sensitivity and specificity of 70.0 and 68.8 %, respectively. A multivariate general estimating equations analysis identified no prior radiation [odds ratio (OR) 0.211 and 0.137, P = 0.033 and 0.0177], and a lower median relative ADC at 1 week and 1 month (OR 0.619 and 0.694, P = 0.0036 and 0.005), as predictors of tumour response. Lower relative ADC values at 1 week and 1 month following radiation distinguished responders from non-responders and may be a promising biomarker of early radiation response.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10585-016-9778-x | DOI Listing |
Nutr J
January 2025
Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Eugeniahemmet T2:02, Stockholm, SE-171 76, Sweden.
Background: mHealth, i.e. mobile-health, strategies may be used as a complement to regular care to support healthy dietary habits in primary care patients.
View Article and Find Full Text PDFJ Hand Ther
January 2025
Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.
Background: The Strengthening and Stretching for Rheumatoid Arthritis of the Hand (SARAH) program is an evidence-based exercise program for adults with hand function difficulties due to rheumatoid arthritis. A self-guided online version of the program has been developed for direct access by patients.
Purpose: To evaluate the delivery of the online program in routine therapy care and its impact on clinical outcomes, before making it widely available.
BMJ Case Rep
January 2025
Department of Medicine, University of Hawai'i at Mānoa John A Burns School of Medicine, Honolulu, Hawaii, USA.
Leuprolide acetate is commonly used to reduce the size of myomas before surgery. Initially, it stimulates pituitary gonadotropin secretion, followed by sustained suppression of gonadal function. However, the impact on pregnancy outcomes from inadvertent exposure remains unclear.
View Article and Find Full Text PDFJMIR Res Protoc
December 2024
Department of Molecular Pathobiology and Cell Adhesion Biology, Mie University Graduate School of Medicine, Tsu, Japan.
Background: Pain inhibits rehabilitation. In rehabilitation at medical institutions, the usefulness of virtual reality (VR) has been reported in many cases to alleviate pain. In recent years, the demand for home rehabilitation has increased.
View Article and Find Full Text PDFEur J Radiol
December 2024
Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, D-81377 Munich, Germany.
Objectives: To evaluate the influence of clinical and procedural factors, particularly the thickness of reactive sclerosis, on clinical outcome of MR-guided high-intensity focused ultrasound (MR-HIFU) for the treatment of symptomatic osteoid osteomas (OO) of the extremities.
Materials And Methods: 18 consecutive patients (median age 19.5y) with symptomatic OO of the extremities eligible for MR-HIFU were enrolled in this ongoing prospective study (German Clinical Trials Register; nr.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!